Roisin Connolly
Medical Oncology · Baltimore, MDNPI 1801063094
Payments from drug & device makers
Across 68 payments — averaging $8252.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$247K
- Macrogenics, Inc.$213K
- Genentech, Inc.$80K
- Merck$13K
- Hoffmann-la Roche Limited$8K
- Gilead$12
Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Education$12100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $246,682 |
| Macrogenics, Inc. | 49 | $212,901 |
| Genentech, Inc. | 8 | $80,046 |
| Merck | 5 | $13,318 |
| Hoffmann-la Roche Limited | 1 | $8,195 |
| Gilead | 1 | $12 |
How this compares
$561,154 in reported general payments places this provider in the 60th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Baltimore
- Dung leBaltimore$18.7M
- Stephanie GaillardBaltimore$12.2M
- Ashraf BadrosBaltimore$7.2M
- Patrick BrownBaltimore$6.6M
- Nilofer AzadBaltimore$6.5M
- Jean Hoffman-CensitsBaltimore$5.7M
- Ranee MehraBaltimore$5.2M
- Michael CarducciBaltimore$4.8M
- Tanguy Lim-SeiwertBaltimore$4.6M
- Mark LevisBaltimore$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.